Form 4: Ionis Pharma EVP Sells Shares After Option Exercise

Ionis Pharmaceuticals' EVP, Chief Development Officer, Richard S. Geary, exercised stock options and subsequently sold shares totaling 34,639 shares in early November 2025.

Summary

• Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals, Inc. (IONS), reported transactions involving the company's common stock.
• On November 5, 2025, Mr. Geary exercised options to acquire 800 shares at $56.78 and 801 shares at $60.89.
• On November 6, 2025, Mr. Geary exercised options to acquire 14,738 shares at $56.78 and 18,300 shares at $60.89.
• Concurrently with the exercises, Mr. Geary sold 800 shares at a weighted average price of $75.01, 801 shares at a weighted average price of $75.01, 14,738 shares at a weighted average price of $76.0972, and 18,300 shares at a weighted average price of $75.421.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Geary on May 6, 2025.
• Following these transactions, Mr. Geary's direct beneficial ownership of common stock stands at 59,657 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions executed under a pre-established 10b5-1 trading plan. These transactions are generally neutral in sentiment as they are part of an executive's personal financial management and not typically indicative of new company-specific news or performance.

Positives

• The executive sold shares at prices significantly higher than their exercise prices, indicating a profitable transaction for the insider and a healthy market price for the company's stock at the time of sale.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by investors as a lack of confidence, although these transactions are often for personal financial planning.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector. It reflects an individual executive's personal financial planning.

Stakeholder Impact

• Shareholders: The transactions represent a routine sale of shares by a key executive, which is generally not considered a significant event unless the volume is unusually large or outside a pre-planned schedule. The sales were at a profit, which could be seen positively regarding the stock's performance.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Stock Options, Share Sale, Executive Compensation, Richard S. Geary, 10b5-1 Plan